which concluded that the frequency with which metoclopramide induced extrapyramidal symptoms was approximately one hundred times more than reported on the label. Further, Dr. Thompson and Professor Ronald B. Stewart represented that acute dystonic reactions are not the most common form of extrapyramidal symptoms from metoclopramide, but that akathisia is the most common. 8 Several district courts have determined that preemption does not apply to state tort claims when a plaintiff alleges that a drug manufacturer failed to adequately warn users of potential side effects. See Laisure-Radke, 426 F.Sup.2d at 1169 (once a generic drug manufacturer holds an approved ANDA, it can strengthen the warning on the label); Peters v. Astrazeneca, L.P., 417 F.Sup.2d 1051, 1056 (W.D.Wis. 2006) (<HOLDING>); McNellis, 2005 U.S.Dist. LEXIS 37505 at *34
holding that the mere fact that the fda does not require a warning on a product label does not necessarily create a conflict holding that a felony of criminal recklessness was not a crime of violence under  16b because it does not require any purposeful conduct and does not necessarily create a risk that force may be used as a means to an end during the commission of the offense holding that the mere determination that removal was improper does not require a district court to award attorneys fees holding that mere disagreement over the proper treatment does not create a constitutional claim holding a mere warning that termination is possible does not per se constitute adverse employment action